ALNYAlnylam PharmaceuticalsHealth Care
$232.68EarningsOct 29, 2026
1D—1W—1M—3M—1Y—
Market cap$32.2BCompany infoRevenue$4.8B52-wk range$205 – $491IndustryBiotechnologyWebsitealnylam.comRelated
Yahoo
EDGAR
CNN
FinvizMarket Beat
Perform
n/a
1 Year
n/a1 Month
n/a1 Week
n/a1 Day
Rank Durability
Persist
n/a
1 Year
n/a6 Month
n/a3 Month
n/aTrend Hold
Business Beat
Profit
n/a
Composite
n/aRevenue
n/aMargin
n/aCash Flow
Money Flow
Pressure
n/a
60 Day
n/a30 Day
n/a5 Day
n/a2 Day
▼ −48.0% · 1YSPY
Weekly rank vs S&P 500 · 52wk
Not enough history to plot
ValuationHow the price is priced — vs cohort and vs its own past
MetricValueUnivSect5-yr range
P / E39.3×2129
51
1900
P / S6.7×1725
9
30
P / FCF59.3×87
71
2202
EV / EBITDA26.0×1625
34
327
P / E (fwd)———
ProfitabilityMargins and returns on capital
MetricValueUnivSect5-yr range
Gross margin79.7%9184
80%
87%
Operating margin20.8%6569
-95%
21%
Net margin16.8%7070
-123%
17%
ROE109.1%9797
-5781%
117%
ROIC40.2%9694
-107%
40%
Financial healthLeverage and liquidity
MetricValueUnivSect5-yr range
Debt / equity0.754535
0.6
31.6
Net debt / EBITDA-2.0×8986
Current ratio3.058475
Interest coverage3.1×3028
Per shareTTM, with year-over-year change
Revenue / share$34.75▲ +95%
EPS (diluted)$5.92▲ +340%
FCF / share$3.92▲ +1142%
Est. EPS growth (fwd)—